Watching Mind Medicine; Traders Circulating HC Wainright Out With Note Saying 'Co's MM-120 Appears Poised To Shine In Phase 2b Anxiety Trial, Underappreciated MM-120 Could Become A Blockbuster Anxiety Treatment, in our view.' With A Buy Rating And $75 PT
Portfolio Pulse from Happy Mohamed
HC Wainright has released a note stating that Mind Medicine's MM-120 appears ready to excel in Phase 2b Anxiety Trial. They believe the underappreciated MM-120 could become a blockbuster anxiety treatment and have given the company a buy rating with a $75 price target.
June 28, 2023 | 4:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mind Medicine's MM-120 is expected to perform well in Phase 2b Anxiety Trial according to HC Wainright, who gave the company a buy rating and a $75 price target.
The positive note from HC Wainright about Mind Medicine's MM-120 and the buy rating with a $75 price target indicates a strong belief in the company's potential. This could lead to increased investor interest and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100